Clinical Trial Update: A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of SHP648, an AAV-based gene transfer for Hemophilia B, is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• SHP648 (SHP648)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia B | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-05-19